Henrik Falhammar1,2*- 1Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden
- 2Department of Molecular Medicine and Surgery, Karolinska Intitutet, Stockholm, Sweden
Introduction
The adrenal glands are on top of each kidney and weight around 4-6 grams each in an adult person, however, they can grow 50% during stress or pregnancy. The hormones from the adrenal glands, i.e., cortisol, aldosterone, adrenal androgens and catecholamines are involved in most of the body systems. Without cortisol, e.g., we would not be able to survive (1). If tumors or hyperplasia arise from the adrenal gland any of these hormones can be produced in excess and give rise to disorders such as pheochromocytoma, primary aldosteronism and Cushing syndrome. Some conditions are common (e.g., adrenal incidentalomas) while others are rare (e.g., adrenal medullary hyperplasia). However, one common feature is that all adrenal disorders are relatively unknown to physicians and most patients have never heard of the adrenal glands. In the following few paragraphs a few examples of adrenal disorders and examples of challenges as well as new findings will be presented.
Primary adrenal insufficiency
The most common form of primary adrenal insufficiency (PAI) in adults from high-income countries is autoimmune adrenalitis while in children it is congenital adrenal hyperplasia (CAH) (2). Another cause of PAI, adrenal tuberculosis, is claimed to be common in low- to middle income countries but very little is known of tuberculosis-induced PAI in high-income setting (3, 4). Novel forms of PAI have emerged such as immune checkpoint inhibitor (ICI) induced PAI, even though ICIs more commonly induce secondary AI (5). Bilateral adrenal metastasis and bilateral adrenal hemorrhage may result in PAI (6, 7). It is estimated that 10-20/100,000 of the population have PAI (2). Long term negative outcomes have been the focus lately, especially complications due to unphysiological glucocorticoid replacement but also adrenal crisis (8, 9). New treatments have been introduced such as modified release glucocorticoids and hydrocortisone administered subcutaneously via pump (8). On the horizon cell-based therapies emerge such as allogeneic adrenocortical cell transplantation and adrenal-like steroidogenic cell manufacturing from either stem cells or lineage conversion of differentiated cells (10).
Congenital adrenal hyperplasia
CAH is considered a rare group of disorders affecting the steroid synthesis of which 21-hydroxylase deficiency is by far the most frequent (11, 12). CAH is one of many genetic disorders of the adrenal glands causing PAI and the most common. The incidence of classic CAH is around 1/15000 according to neonatal screening programs (11). Non-classic CAH does not have apparent cortisol insufficiency but is usually diagnosed due to adrenal androgen excess or due to family screening. The prevalence of non-classic CAH in the general US Caucasian population has been claimed to be 1/200 (13), while in a country such as Sweden with around 10 million inhabitants only 90 cases of non-classic CAH have been diagnosed (14). However, it can be assumed that most patients with non-classic CAH probably never are diagnosed (15). The prevalence needs to be studied in larger cohorts which have been screened for non-classic CAH to be able to have more well-founded data. Moreover, long-term outcome data have emerged over the last few decades (16–18). Though, most studied patients with CAH have been younger than 30 years of age, and only a few above 50 years of age, the age where most long-term outcomes can be expected to appear. Since the introduction of glucocorticoids and mineralocorticoids in the 1950s, no major advancement has been seen until recently when new therapies have begun to emerge such as modified release glucocorticoids, hydrocortisone administered subcutaneously via pump, the CYP17A1 inhibitor abiraterone, corticotropin-releasing hormone-receptor 1 antagonists, corticotropin antibodies, corticotropin receptor (melanocortin 2 receptor [MC2R]) antagonists, as well as gene- and cell-based therapies (11, 19–21).
Adrenal incidentalomas
Adrenal incidentalomas are found in approximately 2% of the adult population and pose a rising challenge for endocrinologists worldwide demanding ever increasing resources to manage (22). Even if overt Cushing syndrome is not present, autonomous cortisol secretion (ACS) seems to be associated with increased mortality (23–25), especially in women below 65 years of age (24). There are even indications that patients with non-functional adrenal tumors have increased mortality (26). Performing adrenalectomy in patients with ACS is controversial (27), but small randomized controlled trials (RCTs) have just begun to be published (28). Moreover, there are many rare forms of adrenal incidentalomas such as adrenal myelolipomas, adrenal cysts and other adrenal lesions that require more studies to improve our understanding and management of these masses (29–31).
Adrenal malignancy
Both adrenocortical cancer (ACC) and adrenal metastasis have poor prognosis (32, 33). Very few RCTs have been done so most treatment recommendations are based on retrospective studies or small clinical trials (34). However, since only 1 new cases of ACC are diagnosed per million, per year (35), large multinational collaborations are required to find new treatments but also to find new genetic and molecular markers.
Pheochromocytoma and paraganglioma
The symptoms and signs of pheochromocytomas and paragangliomas (PPGLs) are diverse and can easily be misinterpreted (36). Even if only pheochromocytomas are found in the adrenal glands, while paragangliomas are found anywhere in the human body, both conditions are usually grouped since both result in catecholamine excess (37). Cardiovascular manifestations of PPGLs can be dramatic and fatal (38). Nowadays most pheochromocytomas are found in the work up of adrenal incidentalomas (36, 39), and the proportion of pheochromocytomas that are found during yearly surveillance of a genetic syndrome increase. Phenoxybenzamine, a non-selective irreversible alpha-adrenoceptor antagonist, has been the standard preoperative treatment but its use has decreased in favor of selective reversible alpha-adrenoceptor antagonists such a doxazosin which are more readily available (40). Some patients use a calcium channel blocker instead or no medication at all preoperatively which is controversial, however, large RCTs are needed to tease out the best preoperative treatment. More and more genetic variants resulting in PPGLs are found increasing our understanding and changing our follow-up of these conditions (37). Metastatic PPGLs can appear many years after the initial surgery and curative therapy can then be difficult to achieve (41).
Primary aldosteronism
Primary aldosteronism (PA) is severely underdiagnosed (42). It has been estimated that 4-14% of all patients with hypertension in primary care have it secondary to primary aldosteronism if properly investigated (43–45). However, the investigations are cumbersome (46, 47), and easier algorithms are urgently needed. Unilateral hypersecretion of aldosterone, usually due to an aldosterone producing adenoma, is seen in approximately half of all patients with PA, with overproduction from both adrenals in the remaining cases, usually due to bilateral idiopathic hyperplasia. The treatment of choice if the patient is operable is adrenalectomy in unilateral PA and mineralocorticoid receptor antagonists (MRAs) for bilateral PA (46). Functional histopathology can improve both histological diagnosis and predict failure after adrenalectomy (48). If PA is left without specific treatment, the risk for cardiovascular diseases, chronic kidney disease and mortality are increased compared to essential hypertension (49). Unilateral adrenalectomy has been considered superior concerning cardiovascular outcomes and quality of life compared to medical treatment in unilateral disease (50, 51). However, the dose of MRA is often suboptimal and an optimal dose may be more equivalent to adrenalectomy in unilateral disease, but this has to be investigated in future studies.
Conclusion
Adrenal disorders are often misdiagnosed, and the management can be challenging. Some disorders are very rare while others are common but the knowledge about them among physicians and the general population are low. More RCTs and collaborations are required to improve the management and our understanding of adrenal disorders. Hopefully, the Section Adrenal Endocrinology at Frontiers in Endocrinology can be a place where new ideas and collaborations will thrive while the challenges are met.
Author contributions
The author confirms being the sole contributor of this work and has approved it for publication.
Funding
This project was supported by grants from the Magnus Bergvall Foundation (grant nr 2022-047).
Conflict of interest
The author is involved in several academic and commercially initiated studies. Consulting fees have been received from Neurocrine Biosciences, Spruce Biosciences, Lundbeck, Diurnal, Roche Diagnostics International, and Adrenas Therapeutics. The author is also the Specialty Chief Editor for Adrenal Endocrinology at Frontiers in Endocrinology.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. New Engl J Med (2019) 381(9):852–61. doi: 10.1056/NEJMra1807486
2. Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. Adrenal insufficiency. Nat Rev Dis Primers (2021) 7(1):19. doi: 10.1038/s41572-021-00252-7
3. Neogi S, Mukhopadhyay P, Sarkar N, Datta PK, Basu M, Ghosh S. Overt and subclinical adrenal insufficiency in pulmonary tuberculosis. Endocr Pract (2021) 27(6):601–6. doi: 10.1016/j.eprac.2020.11.012
4. Lindh JD, Patrova J, Rushworth RL, Mannheimer B, Falhammar H. Tuberculosis of adrenal glands-a population-based case-control study. J Endocr Soc (2023) 7(5):bvad047. doi: 10.1210/jendso/bvad047
5. Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol / Eur Fed Endocr Societies (2022) 187(6):G1–G21. doi: 10.1530/EJE-22-0689
6. Lubomski A, Falhammar H, Torpy DJ, Rushworth RL. The epidemiology of primary and secondary adrenal malignancies and associated adrenal insufficiency in hospitalised patients: an analysis of hospital admission data, NSW, Australia. BMC Endocr Disord (2021) 21(1):141. doi: 10.1186/s12902-021-00787-6
7. Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A. MANAGEMENT OF ENDOCRINE DISEASE: differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur J Endocrinol / Eur Fed Endocr Societies (2018) 179(2):R57–67. doi: 10.1530/EJE-18-0296
8. Husebye ES, Pearce SH, Krone NP, Kampe O. Adrenal insufficiency. Lancet (2021) 397(10274):613–29. doi: 10.1016/S0140-6736(21)00136-7
9. Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises in older patients. Lancet Diabetes Endocrinol (2020) 8(7):628–39. doi: 10.1016/S2213-8587(20)30122-4
10. Graves LE, Torpy DJ, Coates PT, Alexander IE, Bornstein SR, Clarke B. Future directions for adrenal insufficiency: cellular transplantation and genetic therapies. J Clin Endocrinol Metab (2023) 108(6):1273–89. doi: 10.1210/clinem/dgac751
11. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev (2022) 43(1):91–159. doi: 10.1210/endrev/bnab016
12. Gidlöf S, Falhammar H, Thilén A, von Döbeln A, Ritzén M, Wedell A, et al. One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. Lancet Diabetes Endocrinol (2013) 1(1):35–43. doi: 10.1016/S2213-8587(13)70007-X
13. Hannah-Shmouni F, Morissette R, Sinaii N, Elman M, Prezant TR, Chen W, et al. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US ashkenazi jews and caucasians. Genet Med (2017) 19(11):1276–9. doi: 10.1038/gim.2017.46
14. Falhammar H, Frisen L, Hirschberg AL, Nordenskjold A, Almqvist C, Nordenstrom A. Increased prevalence of fractures in congenital adrenal hyperplasia: a Swedish population-based national cohort study. J Clin Endocrinol Metab (2022) 107(2):e475–86. doi: 10.1210/clinem/dgab712
15. Nordenstrom A, Falhammar H. MANAGEMENT OF ENDOCRINE DISEASE: diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency. Eur J Endocrinol / Eur Fed Endocr Societies (2019) 180(3):R127–45. doi: 10.1530/EJE-18-0712
16. Gomes LG, Mendonca BB, Bachega T. Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real? Curr Opin Endocrinol Diabetes Obes (2020) 27(3):155–61. doi: 10.1097/MED.0000000000000545
17. Nordenstrom A, Lajic S, Falhammar H. Long-term outcomes of congenital adrenal hyperplasia. Endocrinol Metab (Seoul) (2022) 37(4):587–98. doi: 10.3803/EnM.2022.1528
18. Falhammar H, Frisen L, Hirschberg AL, Norrby C, Almqvist C, Nordenskjold A, et al. Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. J Clin Endocrinol Metab (2015) 100(9):3520–8. doi: 10.1210/JC.2015-2093
19. Merke DP, Auchus RJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. New Engl J Med (2020) 383(13):1248–61. doi: 10.1056/NEJMra1909786
20. Nordenstrom A, Falhammar H, Lajic S. Current and novel treatment strategies in children with congenital adrenal hyperplasia. Hormone Res Paediatrics (2022). doi: 10.1159/000522260
21. MacKay D, Nordenstrom A, Falhammar H. Bilateral adrenalectomy in congenital adrenal hyperplasia: a systematic review and meta-analysis. J Clin Endocrinol Metab (2018) 103(5):1767–78. doi: 10.1210/jc.2018-00217
22. Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, et al. Adrenal incidentaloma. Endocr Rev (2020) 41(6):775–820. doi: 10.1210/endrev/bnaa008
23. Patrova J, Kjellman M, Wahrenberg H, Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. Endocrine (2017) 58(2):267–75. doi: 10.1007/s12020-017-1400-8
24. Deutschbein T, Reimondo G, Di Dalmazi G, Bancos I, Patrova J, Vassiliadi DA, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol (2022) 10(7):499–508. doi: 10.1016/S2213-8587(22)00100-0
25. Kjellbom A, Lindgren O, Puvaneswaralingam S, Londahl M, Olsen H. Association between mortality and levels of autonomous cortisol secretion by adrenal incidentalomas : a cohort study. Ann Intern Med (2021) 174(8):1041–9. doi: 10.7326/M20-7946
26. Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A. Nonfunctional" adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med (2016) 165(8):533–42. doi: 10.7326/M16-0547
27. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol / Eur Fed Endocr Societies (2016) 175(2):G1–G34. doi: 10.1530/EJE-16-0467
28. Morelli V, Frigerio S, Aresta C, Passeri E, Pugliese F, Copetti M, et al. Adrenalectomy improves blood pressure and metabolic control in patients with possible autonomous cortisol secretion: results of a RCT. Front Endocrinol (Lausanne) (2022) 13:898084. doi: 10.3389/fendo.2022.898084
29. Calissendorff J, Juhlin CC, Sundin A, Bancos I, Falhammar H. Adrenal myelolipomas. Lancet Diabetes Endocrinol (2021) 9(11):767–75. doi: 10.1016/S2213-8587(21)00178-9
30. Calissendorff J, Juhlin CC, Sundin A, Bancos I, Falhammar H. Adrenal cysts: an emerging condition. Nat Rev Endocrinol (2023) 19(7):398–406. doi: 10.1038/s41574-023-00835-2
31. Dogra P, Sundin A, Juhlin CC, Calissendorff J, Falhammar H, Bancos I. Rare benign adrenal lesions. Eur J Endocrinol / Eur Fed Endocr Societies (2023) 188(4):407–20. doi: 10.1093/ejendo/lvad036
32. Calissendorff J, Calissendorff F, Falhammar H. Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids - experience from a single centre spanning three decades. BMC Endocr Disord (2016) 16:15. doi: 10.1186/s12902-016-0095-9
33. Patrova J, Jarocka I, Wahrenberg H, Falhammar H. Clinical outcomes in adrenal incidentaloma: experience from one center. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists (2015) 21(8):870–7. doi: 10.4158/EP15618.OR
34. Padua TC, Marandino L, Raggi D, Hallanger-Johnson J, Kutikov A, Spiess PE, et al. A systematic review of published clinical trials in the systemic treatment of adrenocortical carcinoma: an initiative led on behalf of the global society of rare genitourinary tumors. Clin Genitourin Cancer (2023) 21(1):1–7. doi: 10.1016/j.clgc.2022.10.011
35. Sharma E, Dahal S, Sharma P, Bhandari A, Gupta V, Amgai B, et al. The characteristics and trends in adrenocortical carcinoma: a united states population based study. J Clin Med Res (2018) 10(8):636–40. doi: 10.14740/jocmr3503w
36. Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect (2018) 7(1):186–92. doi: 10.1530/EC-17-0321
37. Calissendorff J, Juhlin CC, Bancos I, Falhammar H. Pheochromocytomas and abdominal paragangliomas: a practical guidance. Cancers (Basel) (2022) 14(4):917. doi: 10.3390/cancers14040917
38. Y-Hassan S, Falhammar H. Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome. Endocrine (2019) 65(3):483–93. doi: 10.1007/s12020-019-02035-3
39. Gruber LM, Hartman RP, Thompson GB, McKenzie TJ, Lyden ML, Dy BM, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab (2019) 104(5):1386–93. doi: 10.1210/jc.2018-01707
40. Kuo EJ, Chen L, Wright JD, McManus CM, Lee JA, Kuo JH. Phenoxybenzamine is no longer the standard agent used for alpha blockade before adrenalectomy for pheochromocytoma: a national study of 552 patients. Surgery (2023) 173(1):19–25. doi: 10.1016/j.surg.2022.05.039
41. Granberg D, Juhlin CC, Falhammar H. Metastatic pheochromocytomas and abdominal paragangliomas. J Clin Endocrinol Metab (2021) 106(5):e1937–52. doi: 10.1210/clinem/dgaa982
42. Gkaniatsa E, Ekerstad E, Gavric M, Muth A, Trimpou P, Olsson DS, et al. Increasing incidence of primary aldosteronism in Western Sweden during 3 decades - yet an underdiagnosed disorder. J Clin Endocrinol Metab (2021) 106(9):e3603–10. doi: 10.1210/clinem/dgab327
43. Xu Z, Yang J, Hu J, Song Y, He W, Luo T, et al. Primary Aldosteronism in Patients in China With Recently Detected Hypertension. J Am Coll Cardiol (2020) 75(16):1913–22. doi: 10.1016/j.jacc.2020.02.052
44. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol (2017) 69(14):1811–20. doi: 10.1016/j.jacc.2017.01.052
45. Libianto R, Russell GM, Stowasser M, Gwini SM, Nuttall P, Shen J, et al. Detecting primary aldosteronism in Australian primary care: a prospective study. Med J Aust (2022) 216(8):408–12. doi: 10.5694/mja2.51438
46. Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: diagnosis and management of primary aldosteronism: the endocrine society guideline 2016 revisited. Eur J Endocrinol / Eur Fed Endocr Societies (2018) 179(1):R19–29. doi: 10.1530/EJE-17-0990
47. Carasel A, Calissendorff J, Avander K, Shabo I, Volpe C, Falhammar H. Ambulatory fludrocortisone suppression test in the diagnosis of primary aldosteronism: safety, accuracy and cost-effectiveness. Clin Endocrinol (2022) 97(6):730–9. doi: 10.1111/cen.14793
48. Volpe C, Hamberger B, Hoog A, Mukai K, Calissendorff J, Wahrenberg H, et al. Primary aldosteronism: functional histopathology and long-term follow-up after unilateral adrenalectomy. Clin Endocrinol (2015) 82(5):639–47. doi: 10.1111/cen.12645
49. Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol (2018) 6(1):41–50. doi: 10.1016/S2213-8587(17)30319-4
50. Huang WC, Chen YY, Lin YH, Chueh JS. Composite cardiovascular outcomes in patients with primary aldosteronism undergoing medical versus surgical treatment: a meta-analysis. Front Endocrinol (Lausanne) (2021) 12:644260. doi: 10.3389/fendo.2021.644260
Keywords: primary adrenal insufficiency (PAI), congenital adrenal hyperplasia, adrenal incidentaloma (AI), adrenocortical adenocarcinoma, pheochoromocytoma, primary aldosteronism (PA)
Citation: Falhammar H (2023) Specialty grand challenge in adrenal endocrinology. Front. Endocrinol. 14:1237733. doi: 10.3389/fendo.2023.1237733
Received: 09 June 2023; Accepted: 26 June 2023;
Published: 06 July 2023.
Edited and Reviewed by:
Jeff M. P. Holly, University of Bristol, United KingdomCopyright © 2023 Falhammar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Henrik Falhammar, henrik.falhammar@ki.se